Mineralys Therapeutics (MLYS) reported a Q2 loss late Tuesday of $2.85 per diluted share, widening from a loss of $0.66 a year earlier.

Analysts polled by FactSet expected a loss of $0.55.

As expected, no revenue was reported for the quarter ended June 30.

Cash and cash equivalents as of June 30 were $661.4 million, which is expected to fund operations into 2028, the company said.